These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23391648)

  • 1. [Chronic myelogenous leukemia].
    Yoshida C
    Rinsho Ketsueki; 2013 Jan; 54(1):61-70. PubMed ID: 23391648
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic myeloid leukemia. Diagnosis, course, prognosis].
    Lacotte-Thierry L; Guilhot F
    Rev Prat; 1999 Feb; 49(3):339-43. PubMed ID: 10189806
    [No Abstract]   [Full Text] [Related]  

  • 3. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
    Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
    J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
    Vaidya S; Ghosh K; Vundinti BR
    Eur J Haematol; 2011 Nov; 87(5):381-93. PubMed ID: 21815933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming drug resistance in chronic myeloid leukemia.
    Cortes J
    Curr Opin Hematol; 2006 Mar; 13(2):79-86. PubMed ID: 16456373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-age drug meets resistance.
    McCormick F
    Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
    [No Abstract]   [Full Text] [Related]  

  • 9. Juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha 2B.
    Agarwal BR; Gulvady A; Joshi K; Khemani S; Currimbhoy ZE
    Indian Pediatr; 1995 Sep; 32(9):1002-4. PubMed ID: 8935266
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
    Tauchi T; Oyashiki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
    [No Abstract]   [Full Text] [Related]  

  • 11. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic myelogenous leukemia therapy beyond imatinib.
    Deininger M
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
    Marcucci G; Perrotti D; Caligiuri MA
    Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
    [No Abstract]   [Full Text] [Related]  

  • 14. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction: chronic myelogenous leukemia (CML).
    Jabbour E; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
    [No Abstract]   [Full Text] [Related]  

  • 16. Trends in the management of chronic myelogenous leukemia.
    Kantarjian H
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S41-5. PubMed ID: 16280112
    [No Abstract]   [Full Text] [Related]  

  • 17. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 18. NCCN: Chronic myelogenous leukemia.
    Wetzler M;
    Cancer Control; 2001; 8(6 Suppl 2):44-8. PubMed ID: 11760557
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in CML.
    Goldman JM
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):270-2, 292. PubMed ID: 17607286
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.